158 related articles for article (PubMed ID: 31567309)
1. Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma.
Prejac J; Kekez D; Belev B; Kocić L; Bulimbašić S; Pleština S
Anticancer Drugs; 2020 Jan; 31(1):76-79. PubMed ID: 31567309
[TBL] [Abstract][Full Text] [Related]
2. Hand-foot skin reaction induced by sorafenib in a hepatocellular carcinoma patient.
Pathania YS
Postgrad Med J; 2020 Aug; 96(1138):495. PubMed ID: 31551240
[No Abstract] [Full Text] [Related]
3. Leukocytoclastic vasculitis complicating cisplatin + radiation treatment for laryngeal cancer: a case report.
Quintanilha JCF; Visacri MB; Amaral LS; Lima CSP; Cintra ML; Moriel P
BMC Cancer; 2017 Dec; 17(1):831. PubMed ID: 29212535
[TBL] [Abstract][Full Text] [Related]
4. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Boeck S; Wollenberg A; Heinemann V
Ann Oncol; 2007 Sep; 18(9):1582-3. PubMed ID: 17761714
[No Abstract] [Full Text] [Related]
5. Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real-life settings.
Tak KY; Nam HC; Choi JY; Yoon SK; Kim CW; Kim HY; Lee SW; Lee HL; Chang UI; Song DS; Yang JM; Kwon JH; Yoo SH; Sung PS; Choi SW; Song MJ; Kim SH; Jang JW
Int J Cancer; 2020 Oct; 147(7):1970-1978. PubMed ID: 32167170
[TBL] [Abstract][Full Text] [Related]
6. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
8. Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Yoshioka N; Kuzuya T; Ito T; Ishizu Y; Honda T; Ishikawa T; Ishigami M; Fujishiro M
Intern Med; 2019 Oct; 58(19):2803-2808. PubMed ID: 31243207
[TBL] [Abstract][Full Text] [Related]
9. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
Yamamoto K; Kuzuya T; Honda T; Ito T; Ishizu Y; Nakamura M; Miyahara R; Kawashima H; Ishigami M; Fujishiro M
Anticancer Res; 2020 Feb; 40(2):665-676. PubMed ID: 32014907
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?
Brandi G; Venturi M; Dika E; Maibach H; Patrizi A; Biasco G
Cutan Ocul Toxicol; 2013 Oct; 32(4):336-8. PubMed ID: 23534992
[TBL] [Abstract][Full Text] [Related]
12. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Ruanglertboon W; Sorich MJ; Rowland A; Hopkins AM
Int J Clin Oncol; 2020 Sep; 25(9):1672-1677. PubMed ID: 32417993
[TBL] [Abstract][Full Text] [Related]
13. Annular leukocytoclastic vasculitis associated with sorafenib administration.
Najarian DJ; Packianathan V; Zeitouni NC
J Drugs Dermatol; 2010 Jun; 9(6):697-8. PubMed ID: 20645534
[TBL] [Abstract][Full Text] [Related]
14. Facial nodulocystic eruption induced by sorafenib in a patient with hepatocellular carcinoma.
Duran-Vian C; Gómez-Fernández C; Navarro-Fernández I; Del Cura LR; Alonso-Buznego L; González-Vela MC; González-López MA
Indian J Dermatol Venereol Leprol; 2020; 86(4):409-411. PubMed ID: 32415051
[No Abstract] [Full Text] [Related]
15. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Chung NM; Gutierrez M; Turner ML
Arch Dermatol; 2006 Nov; 142(11):1510-1. PubMed ID: 17116852
[No Abstract] [Full Text] [Related]
16. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Brandi G; De Lorenzo S; Di Girolamo S; Bellentani S; Saccoccio G; Biasco G
Tumori; 2015 Apr; 101(2):e46-8. PubMed ID: 25702656
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
Leathers JS; Balderramo D; Prieto J; Diehl F; Gonzalez-Ballerga E; Ferreiro MR; Carrera E; Barreyro F; Diaz-Ferrer J; Singh D; Mattos AZ; Carrilho F; Debes JD
J Clin Gastroenterol; 2019 Jul; 53(6):464-469. PubMed ID: 29952857
[TBL] [Abstract][Full Text] [Related]
19. A case of glyburide-induced leukocytoclastic vasculitis.
Henley JK; Blackmon JA; Fraga GR; Rajpara A; Maz M
Dermatol Online J; 2013 Sep; 19(9):19619. PubMed ID: 24050293
[TBL] [Abstract][Full Text] [Related]
20. Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes.
Marusic S; Vlahovic-Palcevski V; Ljubanovic D
Int J Clin Pharmacol Ther; 2009 Oct; 47(10):603-5. PubMed ID: 19825323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
